Westpac Banking Corp Boosts Stock Holdings in Moderna, Inc. (NASDAQ:MRNA)

Westpac Banking Corp grew its holdings in Moderna, Inc. (NASDAQ:MRNA) by 21.9% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 5,132 shares of the company’s stock after purchasing an additional 921 shares during the quarter. Westpac Banking Corp’s holdings in Moderna were worth $213,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Wilmington Savings Fund Society FSB lifted its holdings in Moderna by 295.0% during the fourth quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock worth $33,000 after buying an additional 587 shares during the period. Compass Planning Associates Inc bought a new position in shares of Moderna in the 4th quarter worth $37,000. Venturi Wealth Management LLC lifted its stake in shares of Moderna by 286.2% during the 4th quarter. Venturi Wealth Management LLC now owns 896 shares of the company’s stock worth $37,000 after purchasing an additional 664 shares during the last quarter. Crowley Wealth Management Inc. bought a new stake in Moderna during the fourth quarter valued at about $41,000. Finally, MassMutual Private Wealth & Trust FSB grew its stake in Moderna by 58.2% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company’s stock valued at $44,000 after purchasing an additional 389 shares during the last quarter. 75.33% of the stock is currently owned by institutional investors.

Moderna Trading Down 2.4 %

Shares of MRNA stock opened at $25.11 on Friday. Moderna, Inc. has a twelve month low of $23.76 and a twelve month high of $170.47. The stock has a market cap of $9.71 billion, a P/E ratio of -2.71 and a beta of 2.23. The stock has a 50 day moving average of $33.55 and a 200 day moving average of $43.01.

Analyst Ratings Changes

MRNA has been the topic of a number of recent analyst reports. The Goldman Sachs Group cut shares of Moderna from a “buy” rating to a “neutral” rating and lowered their price target for the company from $99.00 to $51.00 in a report on Wednesday, January 29th. Barclays downgraded shares of Moderna from an “overweight” rating to an “equal weight” rating and lowered their target price for the company from $111.00 to $45.00 in a research note on Tuesday, February 18th. Bank of America reduced their price target on Moderna from $41.00 to $34.00 and set an “underperform” rating on the stock in a research report on Tuesday, February 11th. JPMorgan Chase & Co. lowered their price objective on Moderna from $40.00 to $33.00 and set an “underweight” rating for the company in a research report on Friday, March 21st. Finally, Berenberg Bank upped their target price on Moderna from $33.00 to $42.00 and gave the company a “hold” rating in a research report on Thursday, January 16th. Four research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $59.00.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.